GlobeNewswire 20-Jun-2017 3:00 PM
DUBLIN, Ireland, June 20, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today kicked-off a campaign, in partnership withGlobal Genes, to raise awareness ofthe significant unmet need and challengesfacing individuals and familiesliving withrare diseases. This milestone collaboration between Horizon Pharma and Global Genes, an organization that hasprovided hope and support to people living with rare diseases since 2009,was announced at the2017Biotechnology Innovation Organization(BIO)International Conventionin San Diego.
Every time somebody texts the word RARE to 565-12, Horizon will donate $1 (up to $10,000) to Global Genes. Those who participate will receive a return text with a link to a mobile website where they can upload a photo to share what rare disease they are most passionate about supporting. Horizon will feature select photos on its RAREisTMInstagram page, and encourages individuals to join in raising awareness by posting their photo and message of rare disease support to their favorite social media channel using the hashtag #RAREis.
Everybody has the opportunity to contribute to Global Genes mission to eliminate the challenges associated withrare disease,saidNicole Boice, founder and CEO of Global Genes. From scientists in a lab working to uncover the next targeted compound for a genetic disease, to the pharmaceutical companies pushing forward with clinical research, to the people and their families living with rare diseases who participate in clinical trials, organize fundraisers and further elevate awareness and education about rare diseases. Today, Horizon is making it very easy to lend a hand and raise your voice.
Horizon Pharma makes medicines available for rare diseases that are particularly devastating and isolating, affecting as few as 500 people inthe United Statesand 2,000 worldwide. Inthe United States, a condition is considered "rare" if it affects less than 200,000 people while other countries have different definitions based on population.1
At theBIO International Convention,Horizon Pharma joins innovators from throughout the healthcare sector in drivingnew approaches to healthcare challenges,and rare diseases are particularly daunting there are more than 7,000rare diseasesand only 5 percent have approved treatment options,saidDave Happel, executive vice president, Orphan Business Unit, Horizon Pharma plc. "We are proud to kick off this important campaign at BIO, in partnership with Global Genes, to bringlarge and small biopharmaceutical companies, scientists, inventors, healthcare professionals and patient groups together to help elevate awareness of rare diseases."
About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow@HZNPplcon Twitter or view careers on ourLinkedInpage.
AboutGlobalGenes Guided by its mission to eliminate the challenges of rare disease, Global Genes is a leading rare disease patient advocacy organization with worldwide reach that serves and promotes the needs of patients and families touched by rare and genetic diseases. Since 2009, under the unifying symbol of HOPE and the Blue Denim Genes Ribbons, Global Genes has been building awareness, developing patient-focused education and advocacy tools, and funding patient care programs and early investigative research. For more information visitwww.globalgenes.org. Join the RARE conversation! Follow @GlobalGenes on social media.
Contacts: Tina Ventura Senior Vice President, Investor Relations Investorfirstname.lastname@example.orgRuth Venning Executive Director, Investor Relations Investoremail@example.comU.S. Media Contact: Matt Flesch Executive Director, Product Communicationsmedia@horizonpharma.com Ireland Media Contact: Ray Gordon Gordon MRM firstname.lastname@example.org
Source: Horizon Pharma plc